A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
| ClinicalTrials.gov Identifier |
| NCT05211323 |
| Institution Name |
| National Cancer Institute/ECOG-ACRIN Cancer Research Group |
| Institution Address (Street) |
| 5323 Harry Hines Blvd |
| Institution City |
| Dallas |
| Institution State |
| Texas |
| Institution ZIP Code |
| 75390 |
| Institution Country |
| United States |
| Institution Phone |
| (214) 648-4180 |
| Institution Website |
| david.hsieh@UTSouthwestern.edu |
| Study Coordinator |
| Ellen Siglinsky |
| Study Coordinator Phone |
| (214) 645-9684 |
| Study Coordinator Email |
| ellen.siglinsky@utsouthwestern.edu |
| Study Overview |
| This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) that cannot be removed by surgery (unresectable) or that may have spread from where it first started. |
| Enrollment Information |
| 80 |
| Study Start Date |
| 20220127 |
| Study End Date |
| 20250101 |
| Financial Assistance Available |
| No |